For a patient who developed a globus sensation (tightness/lump in throat) and severe diarrhea while taking metformin, which resolved after stopping the medication, is an in‑person evaluation of the throat required before transitioning to the Foundayo (metformin) formulation?

In-Person Evaluation Not Required Before Transitioning to Foundayo

The globus sensation (lump in throat) that resolved after stopping metformin does not require in-person evaluation before transitioning to Foundayo, as this symptom was almost certainly a metformin side effect rather than a structural throat abnormality.

Understanding the Clinical Picture

The patient's presentation is classic for metformin-induced gastrointestinal adverse effects:

• Severe diarrhea is a well-documented metformin side effect that can occur at any time during therapy, not just at initiation 1, 2
• Globus sensation (tightness/lump in throat) commonly co-occurs with gastrointestinal symptoms and is typically a functional disorder rather than structural pathology 3
• Complete resolution upon discontinuation strongly suggests drug causation rather than organic disease 4, 5

The temporal relationship—symptoms appearing with metformin and resolving after stopping—provides the key diagnostic information.

Why In-Person Evaluation Is Not Necessary

Absence of Red Flags

The patient lacks alarm features that would mandate urgent evaluation 3:

• No dysphagia (actual difficulty swallowing—globus is a sensation without true swallowing impairment)
• No odynophagia (painful swallowing)
• No weight loss (beyond what might be expected from diarrhea)
• No hemoptysis
• No persistent hoarseness
• Symptoms resolved after stopping the medication

Globus as a Functional Symptom

Globus pharyngeus is defined as a sensation of a lump in the throat in the absence of dysphagia or structural abnormality 3. It:

• Improves with eating (distinguishing it from true dysphagia)
• Is more obvious between meals
• Commonly occurs with gastrointestinal symptoms like those from metformin 3
• Represents a functional disorder in the vast majority of cases when no red flags are present 6, 7

Critical distinction: The patient had globus sensation (feeling of lump), not dysphagia (actual swallowing difficulty). These are different entities 3.

Foundayo Transition Considerations

Foundayo's Throat-Related Warnings

The FDA label for Foundayo (orforglipron, a GLP-1 receptor agonist) mentions dysphagia specifically in the context of thyroid C-cell tumor warning signs 8:

• Symptoms to monitor: "mass in the neck, dysphagia, dyspnea, or persistent hoarseness"
• These are warning signs of medullary thyroid carcinoma (MTC), not common side effects

Key Safety Points for Foundayo

Foundayo is contraindicated if 8:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Prior serious hypersensitivity to orforglipron or GLP-1 receptor agonists

Common gastrointestinal effects of Foundayo 8:

• Nausea, vomiting, diarrhea, constipation, abdominal pain
• These are expected GLP-1 receptor agonist effects
• Severe GI reactions occur in ~3% (vs 1% placebo)

Recommended Approach

Before Starting Foundayo (Telehealth Appropriate)

1. Confirm no contraindications 8:

   • No personal/family history of MTC or MEN 2
   • No prior serious hypersensitivity to GLP-1 receptor agonists

2. Document symptom resolution:

   • Confirm globus and diarrhea have completely resolved
   • Verify no new concerning symptoms have emerged

3. Patient counseling 8:

   • Explain expected GI side effects (nausea, diarrhea common with GLP-1 agonists)
   • Teach warning signs requiring immediate evaluation:
     • Severe persistent abdominal pain (pancreatitis)
     • Neck mass, persistent hoarseness, difficulty breathing (thyroid concerns)
     • Signs of dehydration from GI symptoms
   • Discuss that oral contraceptives may be less effective for 30 days after starting/dose increases

4. Gradual titration 9:

   • Start low dose and titrate slowly to minimize GI side effects
   • This is standard practice for all GLP-1 receptor agonists

When In-Person Evaluation IS Needed

Refer for urgent ENT/GI evaluation if any of these develop 3, 10, 11:

• True dysphagia (actual difficulty swallowing, not just sensation)
• Odynophagia (painful swallowing)
• Unintended weight loss
• Hemoptysis
• Persistent hoarseness
• Palpable neck mass
• Symptoms that persist or worsen despite stopping medication

Common Pitfall to Avoid

Do not conflate globus sensation with dysphagia. Globus is a sensation of a lump without actual swallowing difficulty and rarely indicates serious pathology when occurring with metformin-induced GI symptoms 3. True dysphagia (difficulty with food passage) requires investigation 11.

The patient's complete symptom resolution after stopping metformin provides strong evidence this was medication-related functional symptoms, not structural throat pathology requiring visualization before starting alternative diabetes therapy.